Table 2 Multivariable subdistribution hazard models for contralateral breast cancer risk
Factor (reference) | PredictCBC-2.0A | PredictCBC-2.0B |
|---|---|---|
sHR (95% CI) | sHR (95% CI) | |
Age at PBC, years (75th vs. 25th quartile: 66 vs. 48) | 0.87a (0.83–0.90) | 0.82a (0.78–0.85) |
Body mass index, kg/m2 (75th vs. 25th quartile: 28.4 vs. 22.7) | 1.06 (1.03–1.09) | 1.06 (1.03–1.09) |
Parity (75th vs. 25th quartile: 3 vs. 1) | 0.85 (0.82–0.88) | 0.86 (0.83–0.90) |
First-degree family history of BC (yes) | 1.17 (1.12–1.23) | 1.35 (1.29–1.42) |
BRCA mutation | ||
BRCA1 versus non-carrier | 4.79 (4.43–5.17) | – |
BRCA2 versus non-carrier | 3.09 (2.72–4.25) | – |
PRS313b (75th vs. 25th quartile: -0.49 vs. 0.32) | 1.35 (1.31–1.39) | – |
CHEK2 c.1100delC mutation (present) | 2.75 (2.85–3.34) | – |
Nodal status of PBC (positive) | 0.99 (0.93–1.05) | 0.99 (0.93–1.04) |
Tumor size category of PBC, cm | ||
(2,5] versus ≤ 2 | 0.99 (0.94–1.05) | 1.01 (0.96–1.07) |
> 5 versus ≤ 2 | 1.23 (1.10–1.36) | 1.22 (1.09–1.36) |
Morphology of PBC (lobular including mixed) | 1.19 (1.12–1.27) | 1.17 (1.10–1.24) |
Grade of PBC | ||
Moderately differentiated vs. well differentiated (II vs. I) | 0.93 (0.88–0.99) | 0.98 (0.93–1.04) |
Poorly differentiated vs. well differentiated (III vs. I) | 0.85 (0.79–0.91) | 0.95 (0.88–1.01) |
Chemotherapy (yes) | 0.75 (0.70–0.80) | 0.75 (0.70–0.80) |
Radiotherapy to the breast (yes) | 0.93 (0.89–0.98) | 0.95 (0.90–0.99) |
ER with endocrine therapy | ||
Negative/no versus positive/yes | 1.53 (1.43–1.65) | 1.78 (1.67–1.90) |
Positive/no versus positive/yes | 1.95 (1.83–2.07) | 1.94 (1.82–2.06) |
HER2 with trastuzumab therapy | ||
Negative/no versus positive/yes | 1.22 (1.09–1.38) | 1.30 (1.15–1.46) |
Positive/no versus positive/yes | 1.12 (0.97–1.28) | 1.14 (1.00–1.31) |